Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 8Breast Neoplasms 8Multiple Myeloma 6Giant Cell Tumor of Bone 6Prostatic Neoplasms 5Fractures, Bone 4Neoplasm Metastasis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Osteoporosis 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Bone Metastases 2Bone Diseases 2Thyroid Neoplasms 1Recurrence 1Parathyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hormone Refractory Prostate Cancer 1Hodgkin Disease 1

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Castrate-resistant Prostate Cancer × Denosumab × Clear all
NCT01824342 2015-03-05

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Amgen

Phase 3 Completed
18 enrolled 13 charts
Genitourinary

Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡